<b>Introduction</b>: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated unprecedented efficacy in the treatment of type 2 diabetes mellitus (T2DM) and obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.